Tempest Therapeutics Stock Investor Sentiment

TPST Stock  USD 0.82  0.01  1.85%   
Slightly above 55% of Tempest Therapeutics' private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Tempest Therapeutics suggests that some traders are interested. Tempest Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tempest Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Tempest Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Tempest Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
a minute ago at globenewswire.com         
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
Macroaxis News: globenewswire.com
over a week ago at thelincolnianonline.com         
Tempest Therapeutics, Inc. Sees Large Drop in Short Interest
news
over two weeks ago at gurufocus.com         
Tempest Granted Fast Track Designation from the U.S. ...
Gurufocus Stories at Macroaxis
over two weeks ago at seekingalpha.com         
Tempest gets fast track designation from FDA for amezalpat
seekingalpha News
over two weeks ago at globenewswire.com         
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to T...
Macroaxis News: globenewswire.com
over two weeks ago at finance.yahoo.com         
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635
Yahoo News
over two weeks ago at globenewswire.com         
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635
Macroaxis News: globenewswire.com
over two weeks ago at gurufocus.com         
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635
Gurufocus Stories at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Whiting Samuel of 1700 shares of Tempest Therapeutics at 4.8048 subject to Rule 16b-3
Macroaxis News
over a month ago at thelincolnianonline.com         
Tempest Therapeutics, Inc. Short Interest Down 19.5 percent in December
news
over a month ago at gurufocus.com         
Tempest Receives Orphan Drug Designation from the U.S. ...
Gurufocus Stories at Macroaxis
over a month ago at finance.yahoo.com         
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to...
Yahoo News
over a month ago at www.macroaxis.com         
Acquisition by Nicholas Maestas of 200000 shares of Tempest Therapeutics at 0.86 subject to Rule 16b...
Macroaxis News
over two months ago at news.google.com         
Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com
Google News at Macroaxis
over two months ago at investing.com         
Tempest Therapeutics amends rights agreement
Investing News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Tempest Therapeutics that are available to investors today. That information is available publicly through Tempest media outlets and privately through word of mouth or via Tempest internal channels. However, regardless of the origin, that massive amount of Tempest data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tempest Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tempest Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tempest Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tempest Therapeutics alpha.

Tempest Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Favourable Signals For Tempest Therapeutics Numerous Insiders Acquired Stock
11/27/2024
2
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635
12/06/2024
3
Acquisition by Nicholas Maestas of 200000 shares of Tempest Therapeutics at 0.86 subject to Rule 16b-3
01/02/2025
4
Tempest Therapeutics, Inc. Short Interest Down 19.5 percent in December
01/16/2025
5
Acquisition by Whiting Samuel of 1700 shares of Tempest Therapeutics at 4.8048 subject to Rule 16b-3
01/17/2025
6
Tempest Granted Fast Track Designation from the U.S. ...
02/10/2025

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.